NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

Data To Be Presented At AAIC In July

 
• By Mandy Jackson
  
If NewAmsterdam pursues further testing, obicetrapib could offer an oral drug for Alzheimer's disease (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Scrip